- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04971733
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
November 29, 2023 updated by: Eisai Inc.
An Open-Label Phase 1b/2 Study to Assess Safety and Target Engagement of E2814 in Subjects With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.
Study Overview
Study Type
Interventional
Enrollment (Estimated)
13
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Eisai Medical Information
- Phone Number: +1-888-274-2378
- Email: esi_medinfo@eisai.com
Study Locations
-
-
-
London, United Kingdom, WC1N 3BG
- Recruiting
- National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust
-
-
-
-
California
-
La Jolla, California, United States, 92037
- Recruiting
- UC San Diego Altman Clinical and Translational Research Insititute Clinic
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Recruiting
- Indiana University School of Medicine, Health Partners, Adult Neurology Clinic
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Male or female, age 18 to 80 years at the time of informed consent
- Individuals who are confirmed to be mutation positive for presenilin 1 (PSEN1), amyloid precursor protein (APP), or presenilin 2 (PSEN2) gene that is associated with DIAD
- Clinical Dementia Rating - Sum of Boxes (CDR-SB) score 5 to 12 at Screening
- Evidence of positive amyloid status based on historical or screening amyloid PET
- Able to undergo magnetic resonance imaging (MRI), lumbar puncture (LP), PET, and complete all study-related testing and evaluations
- Has a study partner who in the investigator's judgment is able to provide accurate information as to the participant's cognitive and functional abilities, who agrees to provide information at the study visits which require informant input for scale completion
Exclusion Criteria:
- Clinically significant illness that required medical treatment within 8 weeks before the 1st dose or a clinically significant infection that required medical treatment within 4 weeks before 1st dose
- Females who are breastfeeding or pregnant at Screening or Baseline
Females of childbearing potential who:
Within 3 months before screening, did not use a highly effective method of contraception
- Any neurological condition that may be contributing to cognitive impairment above and beyond that caused by the participant's Alzheimer's disease (AD)
- History of transient ischemic attacks, stroke, or seizures within 12 months of Screening
- History of clinically important carotid or vertebrobasilar stenosis, plaque, or other prominent risk factor for stroke or cerebral haemorrhage (including atrial fibrillation and anticoagulation). Low dose aspirin (less than or equal to [<=] 325 milligram [mg] daily) is not exclusionary
- Any current psychiatric diagnosis or symptoms, (example, hallucinations, major depression, or delusions) that could interfere with study procedures in the participant
- Geriatric Depression Scale (GDS) score greater than or equal to 8 at Screening
- Contraindications to MRI scanning, including but not limited to pacemaker/cardiac defibrillator, neurostimulators, ferromagnetic metal implants (example, in skull and cardiac devices other than those approved as safe for use in MRI scanners)
- Evidence of other clinically significant lesions on brain MRI at Screening that could indicate a dementia diagnosis other than AD
- Other significant pathological findings on brain MRI at Screening
- Hypersensitivity to E2814 or any of the excipients, or to any monoclonal antibody (mAb) treatment
- Any immunological disease which is not adequately controlled, or which requires treatment with immunoglobulins, systemic monoclonal antibodies (or derivatives of monoclonal antibodies), systemic immunosuppressants, or plasmapheresis during the study
- With a bleeding disorder of current chronic use of anticoagulants (example, warfarin, dabigatran, rivaroxaban or apixaban) or of clopidogrel is exclusionary. Limited (occasional or isolated) use of anticoagulants/antiplatelet compounds in cases such as surgical procedures
- Have thyroid stimulating hormone outside of normal range. Other tests of thyroid function with results outside the normal range should only be exclusionary if they are considered clinically significant by the investigator
- Hemoglobin A1c (HgbA1c) greater than (>) 8 percent (%) (retesting is permitted if slightly elevated) or poorly controlled insulin-dependent diabetes (including hypoglycemic episodes). Participants may be rescreened after 3 months to allow optimization of diabetic control
- Abnormally low serum vitamin B12 levels for the testing laboratory
- History of human immunodeficiency virus (HIV) infection, history of hepatitis B infection within the past year, history of hepatitis C infection which has not been adequately treated, or history of spirochete infection of the central nervous system (example, syphilis, Lyme, or borreliosis)
- Any other clinically significant abnormalities in physical examination, vital signs, laboratory tests, or ECG at Screening or Baseline which in the opinion of the investigator require further investigation or treatment or which may interfere with study procedures or safety
- Malignant neoplasms within 3 years of Screening (except for basal or squamous cell carcinoma in situ of the skin, or localized prostate cancer in male participant, or localized breast cancer in female participants)
- Answers "yes" to Columbia-Suicide Severity Rating Scale (C-SSRS) suicidal ideation Type 4 or 5, or any suicidal behavior assessment within 6 months before Screening, at Screening, or at the Baseline Visit, or has been hospitalized or treated for any suicidal behavior in lifetime
- Known or suspected history of drug or alcohol abuse or dependence within 2 years before Screening or a positive urine drug test at Screening
- Any other medical conditions (example, cardiac, respiratory, gastrointestinal, renal disease) which are not stably and adequately controlled, or which in the opinion of the investigator could affect the participant's safety or interfere with the study assessments
- Concurrent participation in a clinical study involving any anti-amyloid therapies (including any mAb therapies) within 6 months before Screening
- Concurrent participation in a clinical study involving any anti-tau therapies
- Participated in any other investigational medication or device study in the 3 months or 5 half-lives (whichever is longer) of the medication before Screening
- Planned surgery which requires general anesthesia that would take place during the study
- Visual or hearing impairment that would prevent the participant from performing psychometric tests accurately
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cohort A, Phase 1b and 2: E2814
Participants will receive E2814 as an intravenous infusion at set intervals over 12 weeks in Phase 1b and over 96 weeks in Phase 2.
|
E2814 intravenous infusion.
|
Experimental: Cohort B: E2814
Participants will receive E2814 as an intravenous infusion at set intervals over 52 weeks.
|
E2814 intravenous infusion.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohort A, Phase 1b: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Up to 20 weeks
|
Up to 20 weeks
|
Cohort A, Phase 2 and Cohort B: Number of Participants With TEAEs
Time Frame: Up to 108 weeks
|
Up to 108 weeks
|
Cohort A, Phase 1b: Number of Participants With Serious Adverse Events (SAEs)
Time Frame: Up to 20 weeks
|
Up to 20 weeks
|
Cohort A, Phase 2 and Cohort B: Number of Participants With SAEs
Time Frame: Up to 108 weeks
|
Up to 108 weeks
|
Cohort A, Phase 1b: Number of Participants With Markedly Abnormal Laboratory Values
Time Frame: Up to 20 weeks
|
Up to 20 weeks
|
Cohort A, Phase 2 and Cohort B: Number of Participants With Markedly Abnormal Laboratory Values
Time Frame: Up to 108 weeks
|
Up to 108 weeks
|
Cohort A, Phase 1b: Number of Participants With Clinically Significant Vital Signs Values
Time Frame: Up to 20 weeks
|
Up to 20 weeks
|
Cohort A, Phase 2 and Cohort B: Number of Participants With Clinically Significant Vital Signs Values
Time Frame: Up to 108 weeks
|
Up to 108 weeks
|
Cohort A, Phase 1b: Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
Time Frame: Up to 20 weeks
|
Up to 20 weeks
|
Cohort A, Phase 2 and Cohort B: Number of Participants With Clinically Significant ECG Findings
Time Frame: Up to 108 weeks
|
Up to 108 weeks
|
Cohort A: Change From Baseline in CSF Free and Bound MTBR-tau at 12 Weeks
Time Frame: Baseline up to Week 12
|
Baseline up to Week 12
|
Cohort A: Change From Baseline in Total MTBR-tau at 12 Weeks
Time Frame: Baseline up to Week 12
|
Baseline up to Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cohort A and Cohort B, Cmax: Maximum Observed Plasma Concentration for E2814
Time Frame: Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A and Cohort B, Tmax: Time to Reach the Maximum Plasma Concentration for E2814
Time Frame: Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A and Cohort B, AUC(0-672h): Area Under the Plasma Concentration-time Curve From Zero Time to 672 Hours for E2814
Time Frame: Cohort A, Days 1 and 85: 0-672 hours post-infusion; Cohort B, Day 1 up to Day 449: 0-672 hours post-infusion
|
Cohort A, Days 1 and 85: 0-672 hours post-infusion; Cohort B, Day 1 up to Day 449: 0-672 hours post-infusion
|
Cohort A and Cohort B, Cmax Serum: Maximum Observed Serum Concentration for E2814
Time Frame: Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A and Cohort B, Tmax Serum: Time to Reach the Maximum Serum Concentration for E2814
Time Frame: Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A, Days 1 and 85: 0-24 hours post-infusion; Cohort B: Pre-dose and immediately at the end of the infusion on Day 1 up to Day 449
|
Cohort A and Cohort B, AUC(0-672h) Serum: Area Under the Serum Concentration-time Curve From Zero Time to 672 Hours for E2814
Time Frame: Cohort A, Days 1 and 85: 0-672 hours post-infusion; Cohort B, Day 1 up to Day 449: 0-672 hours post-infusion
|
Cohort A, Days 1 and 85: 0-672 hours post-infusion; Cohort B, Day 1 up to Day 449: 0-672 hours post-infusion
|
CSF Concentrations of E2814
Time Frame: Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 52 weeks
|
Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 52 weeks
|
Serum anti-E2814 Antibody Concentration
Time Frame: Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 12 weeks after last dose (up to 64 weeks)
|
Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 12 weeks after last dose (up to 64 weeks)
|
Plasma anti-E2814 Antibody Concentration
Time Frame: Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 12 weeks after last dose (up to 64 weeks)
|
Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 12 weeks after last dose (up to 64 weeks)
|
Change From Baseline in CSF Concentrations of Total tau (t-tau) and Phosphorylated tau (p-tau)
Time Frame: Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 52 weeks
|
Cohort A: From first dose the study drug up to 12 weeks after last dose (up to 120 weeks); Cohort B: From first dose the study drug up to 52 weeks
|
Change From Baseline in tau Positron Emission Tomography (PET) Signal
Time Frame: Cohort A: Baseline up to 108 weeks; Cohort B: Baseline up to 52 weeks
|
Cohort A: Baseline up to 108 weeks; Cohort B: Baseline up to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 28, 2021
Primary Completion (Estimated)
July 14, 2025
Study Completion (Estimated)
July 14, 2025
Study Registration Dates
First Submitted
July 20, 2021
First Submitted That Met QC Criteria
July 20, 2021
First Posted (Actual)
July 21, 2021
Study Record Updates
Last Update Posted (Actual)
November 30, 2023
Last Update Submitted That Met QC Criteria
November 29, 2023
Last Verified
November 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- E2814-G000-103
- 2020-005728-12 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on E2814
-
Eisai Inc.Completed
-
Washington University School of MedicineNational Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...RecruitingDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
-
Washington University School of MedicineEli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaboratorsRecruitingDementia | Alzheimers Disease | Alzheimers Disease, FamilialUnited States, Canada, Italy, Argentina, Australia, Brazil, Colombia, France, Germany, Ireland, Japan, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom